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The term “pharmacogenetics” was coined in the 1950s
to describe inherited differences in the disposition and
effects of medications and other xenobiotics. Pharma-
cogenetic studies have focused largely on inherited var-
iations in drug metabolism and polymorphisms of the
genes encoding drug-metabolizing enzymes, to elucidate
the molecular basis of these variations (Nebert 1997).
Although genetic polymorphism in drug metabolism re-
mains a primary focus, inherited differences in drug tar-
gets (e.g., receptors, genetic subsets of diseases, etc.) rep-
resent another facet of pharmacogenetics that can be of
equal importance in determining the effects of some
medications. Theoretically, these two determinants of
drug disposition and effects can be used to select the
most appropriate medication for a given disease (e.g.,
pharmacogenetics of receptors) and the optimal dose of
medication for each individual patient (e.g., pharma-
cogenetics of metabolism and disposition). This mini-
review focuses on inherited differences in the metabolism
of selected anticancer agents (for a discussion of the ge-
netic determinants of molecular oncogenesis, see Hart-
sough and Steeg 1998 [in this issue]; Narod 1998 [in
this issue]).
To date, several dozen genetic polymorphisms of drug-
metabolizing enzymes have been identified and charac-
terized (Nebert et al. 1996), some of which are known
to affect anticancer drugs (table 1). The list includes
practically all major classes of drug-metabolizing en-
zymes, including cytochromes P450, N-acetyltransfer-
ases, glutathione and uridine diphosphate glucuronosyl-
transferases, and methylases. Of the two principal
mechanisms leading to differences in drug metabolism,
discoveries of inactivating mutations in the coding
regions or exon/intron boundaries of genes for specific
drug-metabolizing enzymes are far more common than
reports of mutations affecting regulatory mechanisms
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(up- or downregulation of the enzymatic activity) of
these enzymes. Polymorphisms of drug-metaboliz-
ing–enzyme genes also may influence cancer suscepti-
bility, through metabolic activation or inactivation of
xenobiotics and pollutants (Nebert et al. 1996). Exten-
sive reviews on specific polymorphisms can be found
elsewhere (Grant 1993; Gonzalez and Fernandez-Sal-
guero 1995; Krynetski et al. 1996; Meyer and Zanger
1997); here we discuss the thiopurine S-methyltransfer-
ase gene (TPMT), to illustrate the potential importance
of polymorphisms in drug-metabolizing enzymes for
cancer chemotherapy.
Thiopurine Therapy and the TPMT Polymorphism
Mercaptopurine (MP) and thioguanine (TG) are
among the most widely used antileukemic agents, and
azathioprine (an MP prodrug) is a widely prescribed
immunosuppressant. MP and TG are inactive prodrugs,
requiring metabolism to thiopurine nucleotides via the
purine-salvage pathway (e.g., HPRT), to exert cytotox-
icity (Elion 1989).
Alternatively, these two drugs can undergo S-meth-
ylation catalyzed by TPMT or oxidation to thiouric acid
by xanthine oxidase. However, hematopoietic tissues do
not have measurable xanthine oxidase activity, leaving
S-methylation to inactive S-methylated bases as the ma-
jor competing metabolic pathway in these cells. Clinical
studies have established that cellular accumulation of
TG nucleotides (TGNs) is inversely related to TPMT
activity (fig. 1) (Lennard et al. 1990), because high
TPMT activity shunts more drug down the methylation
pathway, leaving less for activation to thioguanosine
mono-, di-, and triphosphates (TGNs). Furthermore,
several studies have documented that TPMT-deficient
patients accumulate very high TGN concentrations in
erythrocytes and presumably other hematopoietic tis-
sues, leading to severe hematopoietic toxicity, unless
their dosage is reduced (Evans et al. 1991). TPMT ac-
tivity typically is measured in erythrocytes, because this
correlates with TPMT activity in other normal (Van
Loon et al. 1992) and neoplastic (McLeod et al. 1995)
tissues. In erythrocytes of TPMT-deficient patients (fig.
1), TGN accumulates to levels 10–20# higher than the
median values of other patients (Lennard et al. 1986).
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Table 1
Cancer Chemotherapy Metabolized by Polymorphic Enzymes
Anticancer Agent
Metabolic Pathway/
Enzyme
Interindividual
Variability Polymorphism Reference
5-fluorouracil Inactivation bydihy-
dropyrimidine
dehydrogenase
10-fold Inherited Diasio et al. 1988;
Wei et al. 1996
MP, TG, azathioprine Inactivation by
TPMT
130-fold Inherited Krynetski et al. 1996
Amonafide Activation by N-
acetyltransferase
13-fold Inherited Ratain et al. 1991
Busulfan Inactivation by glu-
tathione S-
transferase
10-fold ? Czerwinski et al. 1996
Irinotecan Inactivation by uri-
dine diphosphate
glucuronosyl-
transferase
50-fold Inherited Iyer et al. 1998
Cyclophosphamide Activation by cyto-
chrome P450
4–9-fold Inherited Chang et al. 1997
Figure 1 Relationship between TPMT activity in erythrocytes
and TGN accumulation in erythrocytes of children with ALL receiving
uniform MP therapy. Values depicted by circles are from the study by
Lennard et al. (1990; reproduced with publisher’s permission), and
the values depicted by the square and the triangle are for two TPMT-
deficient patients from St. Jude Children’s Research Hospital (de-
scribed in Evans et al. 1991; McLeod et al. 1993).
The potential severity of thiopurine toxicity is illustrated
by the case report of fatal hematopoietic toxicity when
full doses of thiopurines were given to a TPMT-deficient
patient (Schutz et al. 1993). In contrast, TPMT-deficient
patients can be treated successfully with thiopurine med-
ications if their thiopurine dosage is decreased to
6%–10% of the conventional dosage (Evans et al. 1991).
Although the greatest risk of toxicity is in patients with
TPMT deficiency, there are data indicating that patients
with heterozygous phenotypes are at intermediate risk
of thiopurine toxicity (M. V. Relling and W. E. Evans,
unpublished data).
Whereas high TGN levels have been clearly associated
with thiopurine toxicity (Lennard et al. 1986; Evans et
al. 1991), low erythrocyte TGN concentrations can af-
fect the long-term outcome of pediatric acute lympho-
blastic leukemia (ALL) (Lennard and Lilleyman 1989).
Among 95 children with ALL, those with red blood cell
(RBC) TGN levels less than the population median had
significantly higher TPMT activity, compared with those
having TGN levels greater than the population median
value (Lennard et al. 1990), and, more importantly, chil-
dren with lower TGN concentrations had a higher risk
of disease relapse. TPMT activity also may be an im-
portant factor in determining long-term graft survival in
azathioprine-treated patients; it has been suggested that
those with high TPMT activity might benefit from doses
near the upper limit of the dosage generally recom-
mended (Chocair et al. 1992). To optimize thiopurine
dosages, RBC TGN levels should be monitored or
TPMT phenotype or genotype should be determined in
ALL patients treated with extensive MP therapy and in
transplant patients treated with azathioprine.
Genetic Variations in TPMT Activity
TPMT activity in humans, which is inherited as an
autosomal codominant trait, exhibits genetic polymor-
phism; ∼10% of Caucasian and African-American pop-
ulations inherit intermediate activity (i.e., heterozygotes)
and ∼1 in 300 inherit TPMT deficiency (fig. 2) (Wein-
shilboum and Sladek 1980; McLeod et al. 1994). The
genetic basis for the TPMT polymorphism has now been
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Figure 2 Genetic polymorphism of TPMT activity and thiopurine therapy, from bench to bedside and back. Top panel, Distribution of
TPMT activity in most populations (adapted from Krynetski et al. 1996). Right panel, Structure (10 exons) and positions of mutations (in exon
5 for TPMT*2 and in exons 7 and 10 for TPMT*3A) in the most prevalent mutant alleles of TPMT, in Caucasians (more than six others have
now been reported in various ethnic groups). Bottom panel, Results of PCR-based techniques for detection of inactivating mutations at the
human TPMT gene locus. Left panel, Potential extent of MP-dosage reduction to avoid toxicity in patients with inherited deficiency of TPMT
activity.
clearly established by the recent identification of inac-
tivating mutations in the human TPMT gene (Krynetski
et al. 1995; Tai et al. 1996; Szumlanski et al. 1996;
Otterness et al. 1997). Currently, at least eight variant
alleles associated with inheritance of low enzymatic ac-
tivity have been reported. These alleles contain point
mutations leading to amino acid substitutions
(TPMT*2, -*3A, -*3B, -*3C, -*3D, -*5, and -*6), for-
mation of a premature stop codon (TPMT*3D), or de-
struction of a splice site (TPMT*4). The consequences
of amino acid substitutions in alleles TPMT*2, -*3A, -
*3B, and -*3C have been characterized extensively, both
in vitro and in vivo (Tai et al. 1996, 1997).
Although inheritance is the principal determinant of
TPMT activity, other factors also may influence its in
vivo activity. For example, there are data indicating that
patient age, renal function, and thiopurine administra-
tion (Lennard et al. 1990; McLeod et al. 1994) alter
TPMT activity in erythrocytes. Moreover, tissue-specific
expression of TPMT mRNA also has been reported
(Krynetski et al. 1995), with the highest expression of
TPMT mRNA in the liver and kidneys and relatively
low levels in the brain and lungs. However, the molecular
mechanisms and clinical importance of these variations
in TPMT activity remain undefined.
Mechanism of TPMT Deficiency
Heterologous expression of wild-type and several mu-
tant forms of TPMT (TPMT*2, -3A, -3B, and -3C) in
yeast and mammalian cells and northern analysis of pa-
tient samples have indicated that the level of mRNA is
not affected by these mutations (Krynetski et al. 1995;
Tai et al. 1997). Similarly, the synthesis rate of the TPMT
protein in yeast, as well as in vitro translation in rabbit
reticulocyte lysate, was not different for mutant TPMT
cDNAs, compared with wild-type TPMT cDNA. In con-
trast, mutant TPMT proteins (i.e., TPMT*2 and
TPMT*3A) were shown to undergo rapid proteolysis
via an ATP-dependent proteasomal mechanism (Tai et
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al. 1997), with degradation half-lives of ∼0.25 h for the
mutant proteins, compared with 18 h for the wild-type
protein. Furthermore, western analysis of TPMT protein
in erythrocytes of patients revealed a strong correlation
between TPMT protein levels and catalytic activity. It
should be recognized that the natural substrate for
TPMT has not been identified. However, because en-
hanced protein degradation is a primary mechanism for
loss of TPMT activity, with TPMT*2 and TPMT*3A,
which are the predominant mutant alleles in Caucasians
(Yates et al. 1997), individuals inheriting these mutant
alleles will have deficient metabolism of thiopurines
and as-yet-unknown endogenous or environmental
substrates.
Diagnosis of TPMT Deficiency in Patients
One method for assessing TPMT activity in patients
is by means of a biochemical assay of erythrocyte lysates,
by measuring the methylation of 6-MP with (14C-
methyl)-S-adenosylmethionine as the methyl donor
(Weinshilboum et al. 1978). Erythrocytes typically are
used as surrogates for other drug-metabolizing tissues,
since a strong correlation has been established between
TPMT activity in erythrocytes and other tissues, includ-
ing ALL lymphoblasts (Van Loon and Weinshilboum
1982; Woodson et al. 1982; Szumlanski et al. 1992;
McLeod et al. 1995). It should be noted that, in patients
who have received an RBC transfusion within ∼60 d,
the measured TPMT activity may be spurious if a TPMT-
deficient or heterozygous patient is transfused with
blood from a homozygous wild-type individual. This is
illustrated by a TPMT-deficient patient at our hospital
(genotype TPMT*3A/*3A), who had a measured TPMT
activity of 9.8 U/ml pRBC 12 d after receiving two units
of packed erythrocytes, compared with undetectable ac-
tivity 4 mo after the erythrocyte transfusions. Thus, this
patient appeared to be a TPMT heterozygote, on the
basis of erythrocyte TPMT activity, because she had been
transfused with erythrocytes from an individual with
homozygous wild-type TPMT activity.
Because it is not uncommon for newly diagnosed can-
cer patients to receive RBC transfusions, molecular ge-
netic methods have been developed to diagnose TPMT-
deficient patients, by use of genomic DNA (Yates et al.
1997). In a study of Caucasians, the TPMT*2 and
TPMT*3 alleles accounted for 180% of mutant alleles
and yielded 195% concordance between genotype and
phenotype (Yates et al. 1997). Additional rare mutant
alleles have now been identified (Otterness et al. 1997),
some of which may be more prevalent mutant alleles in
other ethnic groups. These discoveries will further en-
hance the reliability of genotyping methods and will per-
mit the development of more robust PCR-based geno-
typing systems to identify TPMT-deficient patients prior
to therapy with MP, azathioprine, or TG, including pa-
tients who have received donor RBC transfusions. Fur-
thermore, “DNA chip” technology has the potential to
completely automate TPMT-genotype determination
and to provide rapid screening for a larger number of
mutant alleles. Given the importance of MP for curative
therapy of ALL and the role of azathioprine immuno-
suppression in organ-transplant recipients (Hollander et
al. 1995), a DNA-based method to prospectively diag-
nose TPMT deficiency offers a clinically important strat-
egy to minimize the risk of potentially life-threatening
hematopoietic toxicity.
TPMT illustrates the potential clinical importance of
genetic polymorphisms in drug metabolism as determi-
nants of toxicity and efficacy of anticancer therapy (fig.
2). Characterization of the molecular mechanisms of this
inherited trait has made it possible to accurately identify
patients who are at high risk of toxicity, thereby pro-
viding a rational way of choosing the dosage of these
important antileukemic and immunosuppressive medi-
cations. Furthermore, adjusting the dose of MP (i.e., a
10–15# decrease as compared with conventional doses)
makes thiopurine therapy as tolerable and effective in
TPMT-deficient patients as it is in those with normal
TPMT activity. Similar studies of other anticancer agents
that are known substrates of polymorphic enzymes (e.g.,
5-fluorouracil, amonafide, and busulfan) may offer
additional mechanism-based guidelines for increasing
the efficacy or decreasing the toxicity of cancer
chemotherapy.
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